According to Eurobio Scientific's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 0. At the end of 2022 the company had a P/E ratio of 8.34.
Year | P/E ratio | Change |
---|---|---|
2022 | 8.34 | 68.7% |
2021 | 4.95 | 92% |
2020 | 2.58 | -83.1% |
2019 | 15.2 | -236.34% |
2018 | -11.2 | 169.99% |
2017 | -4.14 | 32.22% |
2016 | -3.13 | -47.81% |
2015 | -6.00 | -6.9% |
2014 | -6.44 | 5.8% |
2013 | -6.09 | 8.28% |
2012 | -5.63 | -44.28% |
2011 | -10.1 | 12.17% |
2010 | -9.00 | -32.31% |
2009 | -13.3 | 56.71% |
2008 | -8.48 | -49.89% |
2007 | -16.9 |
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.